 |
 
|
|
In addition to his role as Partner and Thought Leader on Depression and Bipolar Disorder, Dr. Goodwin serves as a Professor of Psychiatry at The George Washington University and Director of the University’s Psychopharmacology Research Center where he conducts research on manic-depressive illness. He also directs the Center on Neuroscience, Medical Progress, and Society at the George Washington University Medical Center. At the Center, Dr. Goodwin’s policy studies focus on the impact of changing patterns of health care on quality and innovation in medicine.
Dr. Goodwin is a founding partner of Best Practice, a consulting firm providing expertise to pharmaceutical and biotech companies and managed care organizations worldwide. Dr. Goodwin’s role encompasses many facets including public policy analysis, patient and physician education, and the development of research protocols. A Best Practice study Dr. Goodwin headed found that lithium was significantly more effective than another widely used mood stabilizer protecting against suicide among 26,000 bipolar I patients.
Dr. Goodwin is the former Director of the National Institute of Mental Health (NIMH). Prior to that, he held a Presidential appointment as head of the Alcohol, Drug Abuse, and Mental Health Administration. A physician-scientist specializing in psychiatry and psychopharmacology, Dr. Goodwin served from 1981 to 1988 as NIMH Scientific Director and chief of Intramural Research. He joined the NIMH in 1965 and has become an internationally recognized authority in the research and treatment of major depression and bipolar illness. For example, he was first to report the antidepressant effects of lithium in a controlled study.
A graduate of Georgetown University, Dr. Goodwin received his M.D. from St. Louis University and took his psychiatric residency at the University of North Carolina in Chapel Hill. He is a Member of the Institute of Medicine of the National Academy of Sciences and a Fellow of the ACNP. He serves or has served on the editorial boards of key scientific journals, including the Archives of General Psychiatry, The Journal of Clinical Psychopharmacology, Bipolar Disorders and was a founder and co-editor in chief of Psychiatry Research.
Dr. Goodwin is a recipient of the major research awards in his field including the Hofheimer Prize from the American Psychiatric Association, the A.E. Bennett Award from The Soc. Of Biological Psychiatry, the Psychopharmacology Research Award from the American Psychological Association, the International Anna-Monika Prize for Research in Depression, the Edward A. Strecker Award, the Falcone Prize from NARSAD, the McAlpin Research Award from the National Mental Health Association, the Distinguished Service Award from NAMI, and the Research Award from the American Foundation for Suicide Prevention and the Lifetime Achievement Award from International Review Of Bipolar Disorders He was the first recipient of the Psychiatrist of the Year from Psychiatric Times, and the Fawcett Humanitarian Award of the NDMDA, the Public Service Award from the Federation of American Societies for Experimental Biology (FASEB), and the Hope Award from the Depression and Bipolar Support Alliance (DBSA). In 1998 he was elected and served as President of the Psychiatric Research Society.
The author of over 460 publications, Dr. Goodwin (with K. R. Jamison, Ph.D.) wrote Manic-Depressive Illness, the first psychiatric text to win the Best Medical Book award from the Association of American Publishers. The second edition, Manic Depressive Illness: Bipolar Disorders and Recurrent Depression, was published in March 2007. He is one of five psychiatrists on the Current Contents list of the most frequently cited scientists in the world and one of twelve psychiatrists listed in The Best Doctors in the U.S.
In addition to his work at The George Washington University Medical Center and his private practice, Dr. Goodwin is host of the award winning The Infinite Mind radio show. This one hour national weekly public radio program is dedicated to issues relating to the mind, the brain, and mental illness. The program is now carried in more than 240 markets. Its estimated one million listeners make it the most popular health show in public radio.
|
|
|
|
